Exploration of Clonal Hematopoiesis of Indeterminate Potential in Non-ischemic Heart Failure With Reduced Ejection Fraction - Trial NCT05981144
Access comprehensive clinical trial information for NCT05981144 through Pure Global AI's free database. This phase not specified trial is sponsored by Yonsei University and is currently Completed. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Yonsei University
Timeline & Enrollment
N/A
Nov 23, 2021
Jan 31, 2023
Primary Outcome
Left ventricular reverse remodeling
Summary
Clonal hematopoiesis of indeterminate potential (CHIP) refers to a phenomenon in which blood
 cells with somatic mutation circulate in the peripheral blood due to abnormal proliferation
 and differentiation of mutant hematopoietic cells.
 
 CHIP is considered one of the aging phenomena, and the mutant blood cells increased by CHIP
 cause chronic inflammation, thereby increasing the occurrence of atherosclerotic
 cardiovascular disease. Therefore, CHIP is known to be closely related to poor prognosis of
 ischemic heart failure. Meanwhile, chronic inflammation may be involved in the development of
 non-ischemic myocardial disease, which is one of the major causes of heart failure.
 
 This study will identify CHIP and perform NLRP3 inflammasome assay in 100 non-ischemic heart
 failure patients and evaluate the relationship between CHIP and inflammation, imaging markers
 of heart failure, Left ventricle reverse remodeling after guideline-directed medical
 treatment, and prognosis of heart failure with reduced ejection fraction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05981144
Non-Device Trial